A Single-dose, Dose-escalation Study of a Long-acting MOD-5014 in Healthy Adult Male

Hemophilia A or B With Inhibitors Clinical Trial

Official title:

A Phase 1,Randomized, Single-blind, Placebo-controlled, Single Dose, Dose-escalated Study to Assess the Safety, Pharmacokinetic and Pharmacodynamic Profile of Subcutaneous Administration of a Long-acting Recombinant Factor VIIa in Healthy Adult Males

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02919800
• Other study ID #: CP-5-002
• Status: Completed
• Phase: Phase 1
• Start date: January 22, 2017
• Est. completion date: February 21, 2018

Study information

• Verified date: September 2019
• Source: OPKO Health, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A Phase 1, randomized, single-blind, placebo-controlled, single dose, dose-escalation study to assess the safety, pharmacokinetic and pharmacodynamic profile of subcutaneous administration of a long-acting recombinant factor VIIa (MOD-5014) in healthy adult males.

Description:

This will be a single-dose, randomized, single-blind, placebo-controlled, dose-escalating study.

The study will include four escalating dose groups, with eight subjects in each dose group. Subjects will be randomized in 3:1 ratio to receive a single SC injection of MOD-5014 (n=6) or a placebo (n=2), and will be followed up for 30 days. The initial MOD-5014 dose group will receive 100 µg/kg followed by single doses of 200, 400 and 600 µg/kg administered to subsequent subject cohorts.

The decision to proceed to the higher dose level will be made by a Data Safety Monitoring Board (DSMB) after review of relevant safety data (including adverse events, clinical laboratory and vital signs), collected up to and including 7 days after the last subject of the previous dose group has been dosed.

Common Terminology Criteria for Adverse Events (CTCAE) guidelines will be used to determine maximum tolerated dose (MTD) and dose limiting toxicity (DLT). Dose escalation will be permitted if the prior dose is well tolerated, and there are no safety or tolerability concerns raised by the investigator, sponsor, medical monitor or DSMB over 7 days post-dosing.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 32
• Est. completion date: February 21, 2018
• Est. primary completion date: February 21, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

1. Men, 18-50 years of age, inclusive, at the screening visit.

2. Subjects must provide written informed consent prior to participating in the study.

3. Considered healthy based on medical history, physical examination and clinical laboratory results.

4. Body Mass Index (BMI) 19.0-30.0 kg/m2 and total body weight >50 Kg.

5. Fertile men must agree to use a barrier contraceptive (condom) for 30 days post-dosing and are restricted from donating sperm for 30 days after dosing. Subjects with a vasectomy performed more than 6 months prior to treatment are also acceptable.

6. Supine blood pressure and heart rate within normal limits (systolic 90-140 mmHg; diastolic 50-90 mmHg, heart rate 45-100 beats per minute). No evidence of orthostatic hypotension.

7. Triglyceride = 200 mg/dl

8. ECG with no clinically significant abnormalities recorded at Screening visit and on dosing day (before drug administration): PR interval within 120 and 210 ms, QRS interval < 120 ms, and QTc interval 450 ms.

9. Negative human immunodeficiency virus (HIV), hepatitis B or hepatitis C serology tests at screening.

10. Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

11. Non-smoking and no use of any tobacco or nicotine product by declaration for a period for at least 6 month prior to screening period.

Exclusion Criteria:

1. Family history of blood clots.

2. Have had, within one month prior to study drug administration, a major surgical procedure (e.g. orthopedic, abdominal) or have an elective surgery planned within the study period.

3. Any history of arterial and/or venous thromboembolic events (such as myocardial infarction, ischemic strokes, transient ischemic attacks, deep venous thrombosis or pulmonary embolism).

4. History or current drug/alcohol abuse (excluding use of medicinal cannabis for pain management). History of regular alcohol consumption exceeding - 14 drinks/week for men (1 drink = 5 ounces [150 mL] of wine or 12 ounces [360 mL] of beer or 1.5 ounces [45 mL] of hard liquor) within 6 months of screening. Positive urine drug of abuse (DoA) in screening and on admission. Positive breath alcohol test on admission.

5. Known allergy to any drug. Known allergy or hypersensitivity to any of the test compounds or materials or contraindication to test product.

6. Use of any prescription or over-the-counter (OTC) medications, including vitamins and herbal or dietary supplements within 14 days prior to dosing. Paracetamol for symptomatic relief of pain is allowed until 24 hours prior to the study drug administration.

7. Subjects who have received any vaccines within 4 weeks prior to study drug administration.

8. Participation in another clinical trial within 30 days.

Related Conditions & MeSH terms

• Hemophilia A
• Hemophilia A or B With Inhibitors

Intervention

Biological:
• MOD-5014
MOD-5014, a long-acting modified recombinant Factor VIIa

Other:
• MOD-5014 Placebo
Placebo solution for SC injection containing the same inactive ingredients used in the active drug product at matching volumes

Locations

Country	Name	City	State
Israel	TASMC	Tel-Aviv

Sponsors (1)

Lead Sponsor	Collaborator
OPKO Health, Inc.

Country where clinical trial is conducted

Israel, 

References & Publications (6)

Bysted BV, Scharling B, Møller T, Hansen BL. A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25 degrees C stable formulation. Haemophilia. 2007 Sep;13(5):527-32. — View Citation

Fares FA, Suganuma N, Nishimori K, LaPolt PS, Hsueh AJ, Boime I. Design of a long-acting follitropin agonist by fusing the C-terminal sequence of the chorionic gonadotropin beta subunit to the follitropin beta subunit. Proc Natl Acad Sci U S A. 1992 May 1 — View Citation

Fridberg MJ, Hedner U, Roberts HR, Erhardtsen E. A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjects. Blood Coagul Fibrinolysis. 2005 Jun;16(4):259-66. — View Citation

Klitgaard T, Nielsen TG. Overview of the human pharmacokinetics of recombinant activated factor VII. Br J Clin Pharmacol. 2008 Jan;65(1):3-11. Epub 2007 Oct 24. — View Citation

Møss J, Scharling B, Ezban M, Møller Sørensen T. Evaluation of the safety and pharmacokinetics of a fast-acting recombinant FVIIa analogue, NN1731, in healthy male subjects. J Thromb Haemost. 2009 Feb;7(2):299-305. doi: 10.1111/j.1538-7836.2008.03253.x. E — View Citation

Tanaka KA, Key NS, Levy JH. Blood coagulation: hemostasis and thrombin regulation. Anesth Analg. 2009 May;108(5):1433-46. doi: 10.1213/ane.0b013e31819bcc9c. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Composite safety and tolerability parameters as measured by adverse events, electrocardiograms (ECG), Immunogenicity, laboratory results, vital signs and injection site reactions		within 30 days of injection
Secondary	Cmax of MOD-5014		within 30 days of injection
Secondary	Tmax of MOD-5014		within 30 days of injection
Secondary	AUC(0-t) of MOD-5014		within 30 days of injection
Secondary	AUC(inf) of MOD-5014		within 30 days of injection
Secondary	T(½) of MOD-5014		within 30 days of injection
Secondary	Clearance of MOD-5014		within 30 days of injection